Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Status:
Terminated
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to gain initial insights into the biologic and clinical
effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM). The data may
provide novel insights into anti-PDL-1-induced immunologic changes, which could potentially
be relevant to its future development in Multiple Myeloma (MM) and other indications.